Cardiol Therapeutics Growth Metrics (2021-2022) | CRDL

Growth Metrics Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022
Growth Ratios
Assets Growth (1y) 94.83%107.93%
Assets (QoQ) -15.68%176.56%13.94%-26.67%-10.02%
Cash & Equivalents Growth (1y) -362.27%-131.22%-197.27%
Cash & Equivalents (QoQ) 940.84%-64.49%472.81%-112.39%-23.91%-10.64%
Cash from Investing Activities Growth (1y) -224.75%
Cash from Investing Activities (QoQ) 86.33%-326.68%
Cash from Operations Growth (1y) -46.90%59.26%74.40%
Cash from Operations (QoQ) 11.73%-2.67%37.50%-159.34%75.52%35.50%
EBITDA Margin Growth (1y) -774.00-3185.00-3720.00
EBITDA Margin (QoQ) 293.00-464.00-4973.004,370.00-2118.00-999.00
Enterprise Value Growth (1y) 3,376.14%381.05%-54.92%
Enterprise Value (QoQ) -940.84%609.21%-91.08%593.35%-10.71%-18.33%
FCF Margin Growth (1y) 2,751.00-6675.00-5002.00
FCF Margin (QoQ) 1,566.00-3172.00-3232.007,589.00-7860.00-1499.00
Free Cash Flow Growth (1y) -46.90%59.26%74.40%
Free Cash Flow (QoQ) 11.73%-2.67%37.50%-159.34%75.52%35.50%
Net Cash Flow Growth (1y) -362.27%-116.92%59.06%
Net Cash Flow (QoQ) 280.82%-126.85%1,463.64%-118.81%75.44%35.01%
Property, Plant & Equipment (Net) Growth (1y) 15.63%-100.86%
Property, Plant & Equipment (Net) (QoQ) 37.26%5,619.60%-102.16%-13.02%-49.37%
Revenue Growth (1y) -8.91%-38.57%-25.54%
Revenue (QoQ) 26.35%-54.51%-28.69%25.63%6.30%-39.98%
Share-based Compensation Growth (1y) -50.24%-96.54%3.52%
Share-based Compensation (QoQ) 22.45%-93.13%2,458.78%-76.87%-91.49%105.57%
Shareholder's Equity Growth (1y) 210,968,374.54%31.27%57.86%
Shareholder's Equity (QoQ) 59.77%-16.56%-15.25%186,725,726.94%-100.00%0.35%
Total Debt (QoQ) -32.35%-19.55%-48.19%